Bronchial Allergen Provocation Tests in Asthmatics in Guangzhou
NCT ID: NCT02504528
Last Updated: 2018-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2015-07-01
2018-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
NCT06419413
Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
NCT02360072
Prognosis and Influencing Factors of Asthma in Children Aged 5-12 Years
NCT05765383
Level of FeNO in Chinese Asthma Patients
NCT04125316
Clinical Characteristics of Severe Childhood Asthma
NCT06024902
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
On the second day,the participant undergo bronchial house dust mites challenge tests.
On the third day,the participant undergo the lung function test,airway inflammation evaluation (blood and sputum eosinophils count,IL-13,FeNO)and airway responsiveness tests(methacholine bronchial provocation,nasal histamine provocation).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
allergic asthma
asthma patients that sensitive to house dust mites.
house dust mites
house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
normal controls
normal controls with or without sensitive to house dust mites.
house dust mites
house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
house dust mites
house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sensitive to house dust mite;
* Stable for more than 4 weeks with FEV1≥70%pred
Exclusion Criteria
* upper airway infections within 6 weeks;
* concomitant of hypertension or heart diseases;
* pregnancy
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Firestone Institute for Respiratory Health
OTHER
Guangzhou Institute of Respiratory Disease
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jinping Zheng
Deputy director,GRID
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jinping Zheng
Role: PRINCIPAL_INVESTIGATOR
State Key Laboratory of Respiratory Disease; China Clinical Research Center of Respiratory Disease; First Affiliated Hospital of Guangzhou Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou institute of respiratory disease
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BAPT201534
Identifier Type: REGISTRY
Identifier Source: secondary_id
GIRD201534
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.